PMID- 28696345
DCOM- 20170807
LR  - 20180815
IS  - 1944-7884 (Electronic)
IS  - 1525-4135 (Linking)
VI  - 75
IP  - 5
DP  - 2017 Aug 15
TI  - Optimal HIV Postexposure Prophylaxis Regimen Completion With Single Tablet Daily 
      Elvitegravir/Cobicistat/Tenofovir Disoproxil Fumarate/Emtricitabine Compared With
      More Frequent Dosing Regimens.
PG  - 535-539
LID - 10.1097/QAI.0000000000001440 [doi]
AB  - STRUCTURE: The study evaluated elvitegravir/cobicistat/tenofovir disoproxil
      fumarate (TDF)/emtricitabine (FTC) ("Quad pill") for postexposure prophylaxis
      (PEP). BACKGROUND: HIV-exposed individuals may benefit from PEP, but completion
      rates have been suboptimal because of regimen complexity and side effects. Newer 
      antiretroviral combinations coformulated as single daily pills may optimize PEP
      adherence. SETTING: One hundred HIV-uninfected individuals who presented to a
      Boston community health center after an acute HIV sexual exposure were enrolled
      and initiated PEP with the daily, single-pill combination Quad pill for a 28-day 
      course. METHODS: Side effects and medication completion rates from study
      participants were compared with historical controls who had used PEP regimens
      consisting of TDF/FTC daily and raltegravir twice daily, or earlier regimens of
      twice daily zidovudine (AZT)/lamivudine (3TC) and a protease inhibitor, using chi
      tests for independence. RESULTS: Of the 100 participants who initiated the Quad
      pill for PEP after a high-risk sexual exposure, 71% completed the 28-day Quad
      pill regimen, which was significantly greater than historical controls who used
      TDF/FTC and raltegravir (57%, P < 0.05) or AZT/3TC plus a protease inhibitor
      (39%, P < 0.001). The most common side effects reported by Quad pill users were
      as follows: abdominal discomfort or pain, gas or bloating (42%), diarrhea (38%), 
      fatigue (28%), nausea or vomiting (28%), headache (14%), or dizziness or
      lightheadedness (6%). Most symptoms were mild, limited, and did not result in
      medication discontinuation. No participants became HIV infected. CONCLUSIONS:
      Fixed-dose combination of elvitegravir/cobicistat/TDF/FTC was safe and well
      tolerated for PEP, with higher regimen completion rates than more frequently
      dosed PEP regimens.
FAU - Mayer, Kenneth H
AU  - Mayer KH
AD  - *The Fenway Institute, Fenway Health, Boston, MA;daggerDepartment of Medicine,
      Beth Israel Deaconess Medical Center, Boston, MA;double daggerDepartment of
      Medicine, Harvard Medical School, Boston, MA; section signProctor Foundation,
      University of California San Francisco, San Francisco, CA; ||Department of
      Medicine, Albert Einstein College of Medicine, Bronx, NY;Departments of paragraph
      signEpidemiology;#Behavioral and Social Health Sciences; and**Psychiatry and
      Human Behavior, Brown University, Providence, RI.
FAU - Jones, Daniel
AU  - Jones D
FAU - Oldenburg, Catherine
AU  - Oldenburg C
FAU - Jain, Sachin
AU  - Jain S
FAU - Gelman, Marcy
AU  - Gelman M
FAU - Zaslow, Shayne
AU  - Zaslow S
FAU - Grasso, Chris
AU  - Grasso C
FAU - Mimiaga, Matthew J
AU  - Mimiaga MJ
LA  - eng
GR  - P30 AI060354/AI/NIAID NIH HHS/United States
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, N.I.H., Extramural
PL  - United States
TA  - J Acquir Immune Defic Syndr
JT  - Journal of acquired immune deficiency syndromes (1999)
JID - 100892005
RN  - 0 (Anti-HIV Agents)
RN  - 0 (Elvitegravir, Cobicistat, Emtricitabine, Tenofovir Disoproxil Fumarate Drug
SB  - IM
SB  - X
MH  - Adult
MH  - Anti-HIV Agents/*administration & dosage/adverse effects/*therapeutic use
MH  - Boston
MH  - CD4 Lymphocyte Count
MH  - Drug Administration Schedule
MH  - Drug Therapy, Combination
MH  - Elvitegravir, Cobicistat, Emtricitabine, Tenofovir Disoproxil Fumarate Drug
      Combination/*administration & dosage/adverse effects/*therapeutic use
MH  - Female
MH  - HIV Infections/*drug therapy/prevention & control
MH  - Humans
MH  - Male
MH  - Medication Adherence
MH  - Post-Exposure Prophylaxis/*methods
MH  - Prospective Studies
MH  - Treatment Outcome
MH  - Viral Load
PMC - PMC5606152
MID - NIHMS872895
EDAT- 2017/07/12 06:00
MHDA- 2017/08/08 06:00
CRDT- 2017/07/12 06:00
PHST- 2017/07/12 06:00 [entrez]
PHST- 2017/07/12 06:00 [pubmed]
PHST- 2017/08/08 06:00 [medline]
AID - 10.1097/QAI.0000000000001440 [doi]
AID - 00126334-201708150-00006 [pii]
PST - ppublish
SO  - J Acquir Immune Defic Syndr. 2017 Aug 15;75(5):535-539. doi: